CMS Policy Threatens Access to Home Infusion, Undermines Congressional Intent



THE VALUE OF HOME INFUSION



Home infusion is a cost-effective, convenient, and accessible alternative for patients to receive infused medications when other settings are impractical or unavailable, when transport outside the home is a burden, or when home administration can improve quality of life. Patients with serious infections, cancer, heart failure, immune system diseases, and other conditions can receive treatment at home, where they are comfortable and can resume their personal and professional activities.







Home Infusion Professional Services











Issue Background



Historically, Medicare Part B infusion drugs were reimbursed at the Average Wholesale Price (AWP) with the expectation that the difference would be sufficient to offset the cost of extensive professional pharmacy services needed to administer the drugs.



Congress included provisions in the 21st
Century Cures Act and the Bipartisan
Budget Act of 2018 to lower the drug
reimbursement rate from AWP to the
Average Sales Price (ASP), while also requiring CMS to create a professional services
benefit for Medicare Part B home infusion
drugs, similar to benefits provided by
Medicare Advantage and commercial plans.



In 2018, CMS undermined the policy created by Congress by issuing restrictive regulations that limit reimbursement to days when a nurse is physically present in the patient's home, rather than each day the drug is infused.

	Before 2017	21st Century Cures + BBA	CMS Implementation	Most Commercial Payers
Drugs	95% of AWP	₩ ASP+6%	◆ ASP+6%	A percentage of AWP
Nursing Services	8	Every day drug is infused	Only when a nurse is in the home	Reimbursed separately
Pharmacy Services	8	Every day drug is infused	8	Every day drug is infused

CONGRESSIONAL INTENT



In creating the home infusion professional services benefit for Part B infusion drugs, Congress intended to cover both pharmacy and nursing professional services and specified that providers would be reimbursed for each "infusion drug administration calendar day." Congress intended for this new benefit to be billed with the existing supplies and drug codes for each day a drug was infused in the home.



Since then, bipartisan congressional leaders have reaffirmed that CMS' requirement that a professional be present in the home "contradicts our intent in drafting and enacting this legislation and makes the reimbursement required by the bill inadequate."

United States Senate

The Honorable Seema Verma
Administrator, Center for Medicare and Medicaid Services
200 Independence Avenue, S.W.
Washinaton. D.C. 20201

Dear Administrator Verm

As supporters of the Medicare Home Infusion Therapy Access Act (S. 1738) we are writing it relay our consciens with the Centers for Medicare and Medicaid Services' (CMS') proposed implementation of this law that was passed as part of the Balanced Budger Act of 2018 (Pub. 115-123). It is critical that that this legislation is appropriately implemented to ensure Medic homeficiaries have access to home infusion stating in January 2019.

As part of the proposed rule entitled: "Medicare and Medical Programs," CT 2019 Home Hete Praspective Typung Supern Rule Hybrian CT 2010 Class 4th Authorness Methodology Referencess," Limit Hete Hete Hese Per-basing Medical, Times Heinel Lyanger Heinel Heine Heinel Heine Heinel Heine Heinel Heine Heinel Heine Heinel Heine Heinel Heinel

To remain true to both the legislation and our intent, <u>FMS should withdraw the resultment</u> to the state as usuar as of the preferationable posteroid from the beamed. For reinformant to nector, and instead to recognize that reinformerent be made for each dar. that a home intention force is indicated. The original good of be this was to personant force on treatment to the state of the state of

Our legislation set forth a structure for CMS to reinbourse providers for that "professional services, lechding mensing services." Our intents was that own less flavoir professional services, such as drug preparation, clinical care planning, care coordination, sursing and other associated professional work should be a component of the bone influsion benefit. To the extent that CMS believes these services were covered under the DME benefit, the purpose of the home flusion services appeared was to cover them separately as home influsion benefits and influsion services appoint was to cover them separately as home influsion pervices assistant services.



"To remain true to both the legislation and our intent, CMS should withdraw the requirement that a nurse or other professional be physically present "in the home" for reimbursement to occur, and instead to recognize that reimbursement be made for each day that a home infusion drug is infused."

Impact on Access



Reducing Patients' Quality of Life

- Patient satisfaction for home infusion is extremely high.
- Most patients prefer to receive their infusions in the comfort of their own homes.
- Home infusion is particularly important for patients in rural areas.



No Reimbursement for Pharmacy Services

- Home infusion would be impossible without the expertise of a licensed pharmacist.
- Pharmacists handle the therapy assessment, plan of care development, care coordination, and drug compounding.
- Current CMS policy only recognizes care provided in a patient's home.



Shifting to More Costly and Risky Settings

- CMS' interpretation will shift patients to more expensive settings like hospitals and skilled nursing facilities.
- Hospital-based care puts patients at risk for hospital-acquired infections.



Setting a Dangerous Precedent

- Commercial payers seeking to replicate CMS' approach might believe that "if it's good enough for Medicare, it's good enough for us."
- This practice would quickly undermine home infusion access in the private market, threatening access for all home infusion patients.

